Neurology | New Developments | UNITED STATES

Vizient

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Vizient Announces Novaplus Enhanced Supply Agreement with Pfizer for Six Essential Medications

Lead Product(s): Dexmedetomidine Hydrochloride

Therapeutic Area: Neurology Product Name: Precedex

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Pfizer Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 22, 2020

Details:

Vizient has signed an agreement with Pfizer to add six drugs identified as “essential medications” to its Novaplus® Enhanced Supply Program, part of Vizient’s private label pharmacy solution.

Engrail Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Engrail Therapeutics Raises $32 Million in Series A Financing

Lead Product(s): ENX-101

Therapeutic Area: Neurology Product Name: ENX-101

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Nan Fung Life Sciences

Deal Size: $32.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing June 18, 2020

Details:

The Company plans to use the proceeds from the financing to support the clinical development of its first pipeline asset, ENX-101, a sub-type selective GABA A modulator.

Cyclo Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient

Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Neurology Product Name: Trappsol Cyclo

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 17, 2020

Details:

The final report to FDA states that the drug showed a favorable safety profile as well as encouraging observations of benefit. Safety was monitored by MRIs, ECGs, laboratory safety assessments, and adverse events, all of which supported a favorable safety profile.

Autobahn Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders

Lead Product(s): ABX-002

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: ARCH Venture Partners

Deal Size: $76.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing June 09, 2020

Details:

Proceeds will be used to advance Autobahn’s lead program candidate, ABX-002, a thyroid hormone receptor beta agonist therapy for the treatment of multiple sclerosis (MS) and adrenomyeloneuropathy (AMN).

Axial Biotherapeutics, Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Axial Biotherapeutics to Present Virtual Presentation at American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting

Lead Product(s): Undisclosed

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 22, 2020

Details:

Presentation will focus on the development of novel therapeutics focused on treating Central Nervous System (CNS) indications via the gut-brain axis at the American Society of Clinical Psychopharmacology (ASCP).

Axcella Health

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Axcella Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option

Lead Product(s): AXA1665

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: J.P. Morgan

Deal Size: $60.1 million Upfront Cash: Undisclosed

Deal Type: Public Offering May 18, 2020

Details:

Axcella intends to use the net proceeds to advance its current liver programs, including its planned IND filing for AXA1665 and ensuing initiation of a Clinical Trial and its planned IND filing for AXA1125 in adults and pediatric patients and trial of AXA4010.

Cyclo Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Cyclo Therapeutics Reports Publication of International Patent Application for Treatment of Alzheimer’s Disease

Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

The patent application describes treating Alzheimer’s Disease with the Company’s Trappsol® Cyclo™ hydroxypropyl beta cyclodextrin product.

Travecta Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Travecta Therapeutics Secures $15 Million in Financing

Lead Product(s): TVT-004

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: TKS1

Deal Size: $15.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing May 12, 2020

Details:

The proceeds from the Series A financing will be used to support Travecta's growth and advance the development of TVT-004, Travecta's lead non-opioid product targeting pain.

TissueTech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

TissueTech Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. Food and Drug Administration

Lead Product(s): TTAX02

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2020

Details:

RMAT designation reinforces clinical significance of investigational biologic product TTAX02 used during in-utero fetal surgical repair of spina bifida.

Affinia Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Affinia Therapeutics Raises $60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies

Lead Product(s): Gene therapies

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Atlas Venture

Deal Size: $60.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing March 31, 2020

Details:

The proceeds will be used to advance the company’s platform and develop transformative gene therapies for people affected by muscle and central nervous system (CNS) diseases with significant unmet need.

Find

Find Novel Neurology Drugs in Clinical Development in UNITED STATES

United States

Product Type

Companies

Vizient

Vizient Announces Novaplus Enhanced Supply Agreement with Pfizer for Six Essential Medications

Engrail Therapeutics

Engrail Therapeutics Raises $32 Million in Series A Financing

Cyclo Therapeutics

Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient

Autobahn Therapeutics

Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders

Axial Biotherapeutics, Inc

Axial Biotherapeutics to Present Virtual Presentation at American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting

Axcella Health

Axcella Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option

Cyclo Therapeutics

Cyclo Therapeutics Reports Publication of International Patent Application for Treatment of Alzheimer’s Disease

Travecta Therapeutics

Travecta Therapeutics Secures $15 Million in Financing

TissueTech

TissueTech Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. Food and Drug Administration

Affinia Therapeutics

Affinia Therapeutics Raises $60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies